Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
Berchanhimez (talk | contribs) i made a booboo earlier |
|||
| (43 intermediate revisions by 14 users not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox |
{{Navbox with collapsible groups |
||
| name = Oral hypoglycemics and insulin analogs |
| name = Oral hypoglycemics and insulin analogs |
||
| title = Oral [[ |
| title = Oral [[diabetes medication]], [[insulin]]s and [[insulin analog]]s, and other drugs used in diabetes ([[ATC code A10|A10]]) |
||
| state = {{{state<includeonly>| |
| state = {{{state<includeonly>|expanded</includeonly>}}} |
||
| listclass = hlist |
| listclass = hlist |
||
| group1 = [[Insulin]] |
| group1 = [[Insulin]]s / [[insulin analog]]s |
||
| list1 = {{Navbox|child |
| list1 = {{Navbox|child |
||
| group1 = |
| group1 = ''fast-acting'' |
||
| list1= |
|||
* [[Insulin aspart]] |
|||
* [[Insulin glulisine]] |
|||
* [[Insulin lispro]] |
|||
| group2 = ''short-acting'' |
|||
| list2 = |
|||
* [[Regular insulin]]<sup>#</sup> |
|||
| group3 = ''long-acting'' |
|||
| list3 = |
|||
* [[Insulin detemir]]<sup>#</sup> |
|||
* [[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
|||
* [[NPH insulin]] |
|||
* [[Lente insulin]]<sup>‡</sup> |
|||
* [[Ultralente insulin]]<sup>‡</sup> |
|||
| group4 = ''ultra-long-acting'' |
|||
| list4 = |
|||
* [[Insulin degludec]]<sup>#</sup> ([[Insulin degludec/insulin aspart|+insulin aspart]], [[Insulin degludec/liraglutide|+liraglutide]]) |
|||
* [[Insulin icodec]]<sup>†</sup> ([[Insulin icodec/semaglutide|+semaglutide]]) |
|||
| group5 = ''[[Inhalable insulin|inhalable]]'' |
|||
| list5 = |
|||
* Exubera<sup>‡</sup> |
|||
* Afrezza |
|||
}} |
|||
{{PharmNavFootnote}} |
|||
| group2 = Non-insulins |
|||
| list2= {{navbox|child| |
|||
| group1 = [[Anti-diabetic medication#Sensitizers|Insulin sensitizers]] |
|||
| list1 = {{Navbox|child |
| list1 = {{Navbox|child |
||
| group1 = [[Biguanide]]s |
| group1 = [[Biguanide]]s |
||
| list1 = |
| list1 = |
||
*[[Buformin]]<sup>‡</sup> |
* [[Buformin]]<sup>‡</sup> |
||
*[[Metformin]]<sup>#</sup> |
* [[Metformin]]<sup>#</sup> |
||
*[[Phenformin]]<sup>‡</sup> |
* [[Phenformin]]<sup>‡</sup> |
||
| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]]) |
| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]]) |
||
| list2 = |
| list2 = |
||
*[[Ciglitazone]]<sup>§</sup> |
* [[Ciglitazone]]<sup>§</sup> |
||
*[[Darglitazone]]<sup>§</sup> |
* [[Darglitazone]]<sup>§</sup> |
||
*[[Englitazone]]<sup>§</sup> |
* [[Englitazone]]<sup>§</sup> |
||
*[[Lobeglitazone]] |
* [[Lobeglitazone]] |
||
*[[Netoglitazone]]<sup>§</sup> |
* [[Netoglitazone]]<sup>§</sup> |
||
*[[Pioglitazone]] |
* [[Pioglitazone]] |
||
*[[Rivoglitazone]]<sup>†</sup> |
* [[Rivoglitazone]]<sup>†</sup> |
||
*[[Rosiglitazone]] |
* [[Rosiglitazone]] |
||
*[[Troglitazone]]<sup>‡</sup> |
* [[Troglitazone]]<sup>‡</sup> |
||
| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]] |
| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]] |
||
| list3 = |
| list3 = |
||
*[[Aleglitazar]]<sup>†</sup> |
* [[Aleglitazar]]<sup>†</sup> |
||
*[[Muraglitazar]]<sup>§</sup> |
* [[Muraglitazar]]<sup>§</sup> |
||
*[[Saroglitazar]] |
* [[Saroglitazar]] |
||
*[[Tesaglitazar]]<sup>§</sup> |
* [[Tesaglitazar]]<sup>§</sup> |
||
| group4 = [[Amylin]] analogs and [[DACRA]]s |
|||
| list4 = |
|||
* [[Cagrilintide]]<sup>§</sup> |
|||
* [[Pramlintide]] |
|||
}} |
}} |
||
| Line 47: | Line 84: | ||
| group1 = [[Sulfonylurea]]s |
| group1 = [[Sulfonylurea]]s |
||
| list1 = |
| list1 = |
||
*''1st generation'': [[Acetohexamide]] |
* ''1st generation'': [[Acetohexamide]] |
||
*[[Carbutamide]] |
* [[Carbutamide]] |
||
*[[Chlorpropamide]] |
* [[Chlorpropamide]] |
||
*[[Glycyclamide]] |
* [[Glycyclamide]] |
||
*[[Metahexamide]] |
* [[Metahexamide]] |
||
*[[Tolazamide]] |
* [[Tolazamide]] |
||
*[[Tolbutamide]] |
* [[Tolbutamide]] |
||
*''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]] |
* ''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]] |
||
*[[Glibornuride]] |
* [[Glibornuride]] |
||
*[[Glicaramide]] |
* [[Glicaramide]] |
||
*[[Gliclazide]]<sup>#</sup> |
* [[Gliclazide]]<sup>#</sup> |
||
*[[Glimepiride]] |
* [[Glimepiride]] |
||
*[[Glipizide]] |
* [[Glipizide]] |
||
*[[Gliquidone]] |
* [[Gliquidone]] |
||
*[[Glisoxepide]] |
* [[Glisoxepide]] |
||
*[[Glyclopyramide]] |
* [[Glyclopyramide]] |
||
| group2 = [[Meglitinide]]s/"glinides" |
| group2 = [[Meglitinide]]s/"glinides" |
||
| list2 = |
| list2 = |
||
*[[Mitiglinide]] |
* [[Mitiglinide]] |
||
*[[Nateglinide]] |
* [[Nateglinide]] |
||
*[[Repaglinide]] |
* [[Repaglinide]] |
||
}} |
}} |
||
| Line 75: | Line 112: | ||
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] |
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] |
||
| list2 = |
| list2 = |
||
*[[Albiglutide]]<sup>‡</sup> |
* [[Albiglutide]]<sup>‡</sup> |
||
* [[Danuglipron]]<sup>†</sup> |
|||
*[[Dulaglutide]] |
|||
*[[ |
* [[Dulaglutide]] |
||
*[[ |
* [[Exenatide]] |
||
*[[ |
* [[Liraglutide]] |
||
*[[ |
* [[Lixisenatide]] |
||
*[[ |
* [[Orforglipron]]<sup>§</sup> |
||
* [[Semaglutide]] |
|||
* [[Taspoglutide]]<sup>†</sup> |
|||
{{navbox|child| |
|||
group1=[[GLP1 poly-agonist peptides]] |
|||
|list1= |
|||
* [[Mazdutide]] (GLP-1/[[Glucagon receptor|GCGR]]) |
|||
* [[Retatrutide]]<sup>§</sup> (GLP-1/GIP/GCGR) |
|||
* [[Tirzepatide]] (GLP-1/GIP) |
|||
}} |
|||
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
||
| list3 = |
| list3 = |
||
*[[Alogliptin]] |
* [[Alogliptin]] |
||
*[[Anagliptin]] |
* [[Anagliptin]] |
||
*[[Evogliptin]] |
* [[Evogliptin]] |
||
*[[Garvagliptin]] |
* [[Garvagliptin]] |
||
*[[Gemigliptin]] |
* [[Gemigliptin]] |
||
*[[Gosogliptin]] |
* [[Gosogliptin]] |
||
*[[Linagliptin]] |
* [[Linagliptin]] |
||
*[[Melogliptin]] |
* [[Melogliptin]] |
||
*[[Omarigliptin]] |
* [[Omarigliptin]] |
||
*[[ |
* [[Retagliptin]] |
||
*[[ |
* [[Saxagliptin]] |
||
*[[ |
* [[Sitagliptin]] |
||
*[[ |
* [[Teneligliptin]] |
||
*[[ |
* [[Trelagliptin]] |
||
* [[Vildagliptin]] |
|||
}} |
|||
| group4 = [[Free fatty acid receptor 1|Free fatty acid receptor 1 (GPR40)]] |
|||
|group3 = Other |
|||
|list3 = {{navbox|child |
|||
*[[Fasiglifam]]<sup>†</sup> |
|||
}} |
|||
| group3 = [[Insulin analog|Analog]]s/other insulins |
|||
| list3 = |
|||
*''fast-acting'' |
|||
**[[Insulin aspart]] |
|||
**[[Insulin glulisine]] |
|||
**[[Insulin lispro]] |
|||
*''short-acting'' |
|||
**[[Regular insulin]] |
|||
*''long-acting'' |
|||
**[[Insulin detemir]] |
|||
**[[Insulin glargine]] ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
|||
**[[NPH insulin]] |
|||
**[[Lente insulin|Lente]]<sup>‡</sup>/[[Ultralente]]<sup>‡</sup> |
|||
*''ultra-long-acting'' |
|||
**[[Insulin degludec]] ([[Insulin degludec/liraglutide|+liraglutide]]) |
|||
*''[[Inhalable insulin|inhalable]]'' |
|||
**Exubera<sup>‡</sup> |
|||
**Afrezza |
|||
}} |
|||
| group2 = Other |
|||
| list2 = {{Navbox|child |
|||
| evenodd = swap |
|||
| group1 = [[Aldose reductase inhibitor]]s |
| group1 = [[Aldose reductase inhibitor]]s |
||
| list1 = |
| list1 = |
||
*[[Epalrestat]] |
* [[Epalrestat]] |
||
*[[Fidarestat]]<sup>§</sup> |
* [[Fidarestat]]<sup>§</sup> |
||
*[[Ranirestat]]<sup>†</sup> |
* [[Ranirestat]]<sup>†</sup> |
||
*[[Tolrestat]]<sup>‡</sup> |
* [[Tolrestat]]<sup>‡</sup> |
||
*[[Zenarestat]]<sup>§</sup> |
* [[Zenarestat]]<sup>§</sup> |
||
| group2 = [[Alpha-glucosidase inhibitor]]s |
| group2 = [[Alpha-glucosidase inhibitor]]s |
||
| list2 = |
| list2 = |
||
*[[Acarbose]] |
* [[Acarbose]] |
||
*[[Miglitol]] |
* [[Miglitol]] |
||
*[[Voglibose]] |
* [[Voglibose]] |
||
| |
| group4 = [[Gliflozin|SGLT2 inhibitors]]/"gliflozins" |
||
| list3 = |
|||
*[[Pramlintide]] |
|||
| group4 = [[Gliflozin|Sodium glucose transporter (SGLT2) inhibitors]]/"gliflozins" |
|||
| list4 = |
| list4 = |
||
*[[Canagliflozin]] |
* [[Canagliflozin]] |
||
*[[Dapagliflozin]] |
* [[Dapagliflozin]] |
||
*[[Empagliflozin]] |
* [[Empagliflozin]]<sup>#</sup> |
||
*[[Ertugliflozin]] |
* [[Ertugliflozin]] |
||
*[[Ipragliflozin]] |
* [[Ipragliflozin]] |
||
* [[Luseogliflozin]] |
|||
*[[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup> |
|||
*[[ |
* [[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup> |
||
*[[ |
* [[Sergliflozin etabonate|Sergliflozin]]<sup>§</sup> |
||
* [[Sotagliflozin]] |
|||
* [[Tofogliflozin]]<sup>†</sup> |
|||
* [[Velagliflozin]] |
|||
| group5 = Other |
| group5 = Other |
||
| list5 = |
| list5 = |
||
*[[Benfluorex]]<sup>‡</sup> |
* [[Benfluorex]]<sup>‡</sup> |
||
*[[Bromocriptine]] |
* [[Bromocriptine]] |
||
* [[Imeglimin]] |
|||
}} |
|||
| group6 = [[Combination drug|Combined formulations]] |
|||
|group4 = [[Combination drug|Combinations]] |
|||
| list6 = |
|||
|list4 = {{navbox|child |
|||
|list1 = |
|||
* [[Alogliptin/metformin]] |
* [[Alogliptin/metformin]] |
||
* [[Canagliflozin/metformin]] |
|||
* [[Cagrilintide/semaglutide]]<sup>§</sup> |
|||
* [[Dapagliflozin/metformin]] |
|||
* [[Dapagliflozin/saxagliptin]] |
|||
* [[Dapagliflozin/saxagliptin/metformin]] |
|||
* [[Empagliflozin/linagliptin]] |
|||
* [[Empagliflozin/metformin]] |
|||
* [[Gemigliptin/rosuvastatin]] |
* [[Gemigliptin/rosuvastatin]] |
||
* [[Glibenclamide/metformin|Glibenclamide (glyburide)/metformin]] |
|||
* [[Glimepiride/pioglitazone]] |
|||
* [[Glimepiride/rosiglitazone]] |
* [[Glimepiride/rosiglitazone]] |
||
* [[Linagliptin/metformin]] |
|||
* [[Insulin degludec/insulin aspart]] |
|||
* [[Insulin degludec/liraglutide]] |
|||
* [[Insulin glargine/lixisenatide]] |
|||
* [[Linagliptin/empagliflozin]] |
|||
* [[Metformin/acarbose]] |
* [[Metformin/acarbose]] |
||
* [[Metformin/canagliflozin]] |
|||
* [[Metformin/dapagliflozin]] |
|||
* [[Metformin/empagliflozin]] |
|||
* [[Metformin/ertugliflozin]] |
* [[Metformin/ertugliflozin]] |
||
* [[Metformin/evogliptin]] |
* [[Metformin/evogliptin]] |
||
* [[Metformin/gemigliptin]] |
* [[Metformin/gemigliptin]] |
||
* [[Metformin/linagliptin]] |
|||
* [[Metformin/pioglitazone]] |
|||
* [[Metformin/repaglinide]] |
* [[Metformin/repaglinide]] |
||
* [[Metformin/saxagliptin]] |
|||
* [[Metformin/saxagliptin/dapagliflozin]] |
|||
* [[Metformin/sitagliptin]] |
|||
* [[Metformin/sulfonylureas]] |
* [[Metformin/sulfonylureas]] |
||
* [[Metformin/ |
* [[Metformin/teneligliptin]] |
||
* [[Phenformin/sulfonylureas]] |
* [[Phenformin/sulfonylureas]] |
||
* [[Pioglitazone/alogliptin]] |
* [[Pioglitazone/alogliptin]] |
||
* [[Pioglitazone/glimepiride]] |
|||
* [[Pioglitazone/metformin]] |
|||
* [[Pioglitazone/sitagliptin]] |
* [[Pioglitazone/sitagliptin]] |
||
* [[Rosiglitazone/metformin]] |
* [[Rosiglitazone/metformin]] |
||
* [[Saxagliptin/ |
* [[Saxagliptin/metformin]] |
||
* [[Dapagliflozin/sitagliptin|Sitagliptin/dapagliflozin]] |
|||
* [[Sitagliptin/ertugliflozin]] |
* [[Sitagliptin/ertugliflozin]] |
||
* [[Sitagliptin/ |
* [[Sitagliptin/metformin]] |
||
* [[Simvastatin/sitagliptin|Sitagliptin/simvastatin]] |
|||
* [[Vildagliptin/metformin]] |
|||
}} |
}} |
||
}} |
|||
<!-- group3 omitted to preserve alternating striping --> |
|||
| list4 = |
|||
{{PharmNavFootnote}} |
{{PharmNavFootnote}} |
||
}} |
|||
<noinclude> |
|||
{{Collapsible option}} |
{{Collapsible option}} |
||
[[Category:Drug templates by ATC]] |
[[Category:Drug templates by ATC]] |
||
Latest revision as of 20:21, 3 January 2025
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.